African American Cardiovascular Pharmacogenomics Consortium (ACCOuNT)

The African American Cardiovascular Pharmacogenomics Consortium (ACCOuNT) assembled an observational cohort to characterize genetic and clinical determinants of inter‑individual variability in warfarin dose requirements among participants of African ancestry receiving anticoagulation care. The submission includes individual‑level genotypes in PLINK format (.bed/.bim/.fam) and a harmonized phenotype file with stable warfarin dose, age, height, weight, and concomitant medication indicators (aspirin, amiodarone) for 309 participants. Biospecimens are germline DNA from peripheral blood; no tumor samples and no case–control disease labels are involved. The resource is intended to enable discovery and validation of pharmacogenomic loci, development of dose‑prediction models, and methods benchmarking focused on underrepresented populations. Data available through dbGaP comprise the genotype files, the subject‑level phenotype dataset, and minimal sample metadata needed to link subjects to biospecimens.]]>

非裔美国人心血管药物基因组学联盟（African American Cardiovascular Pharmacogenomics Consortium，ACCOuNT）组建了一项观察性队列，旨在阐明非洲血统抗凝诊疗人群中，华法林剂量需求个体间差异的遗传与临床决定因素。本次提交的数据包含PLINK格式（.bed/.bim/.fam）的个体水平基因型文件，以及一份标准化表型文件，涵盖309名受试者的稳定华法林剂量、年龄、身高、体重，与合并用药指标（阿司匹林、胺碘酮）。所用生物标本均为外周血来源的生殖系DNA，未涉及肿瘤样本及病例对照疾病标签。该数据集资源旨在助力药物基因组位点的发现与验证、剂量预测模型的开发，以及面向代表性不足人群的方法基准测试。可通过dbGaP获取的数据包括基因型文件、受试者水平表型数据集，以及用于关联受试者与生物标本的最小样本元数据。